Moderna raises annual revenue forecast amid strong COVID vaccine demand overseas - The News International
On Friday, Moderna upgraded its full-year sales outlook after strong international demand for its COVID-19 vaccine and collaboration revenues enabled the biotech to achieve profitability in the third quarter.
The robust results provide fresh momentum for Moderna’s drive to expand beyond pandemic products through its newly approved flu vaccine and an experimental personalized cancer vaccine, alongside additional pipeline assets to drive enduring expansion for its mRNA franchise.
Moderna now expects total revenue to grow 15% to 25% in 2026 exceeding its previous projection of up to 10% expansion. It anticipates approximately half of annual revenue to originate from overseas markets.
The US FDA cleared Moderna’s flu vaccine, mFlusiva in August for people 50 and up clearing the way for the inaugural messenger RNA seasonal flu immunization.
Moderna and partner Merck announced last month that their personalized cancer vaccine, combined with Merck’s immunotherapy Keytruda mitigated the risk of melanoma recurrence or death by 42% in a large trial potentially ushering in a new age of cancer treatment. The data compiled by LSEG indicated that the company reported third-quarter revenue of $1.3 billion which smashed analysts’ average prediction of $885.1 million.
